A new vaginal cream containing a reawakened protein could someday prevent the transmission of HIV.
Scientists at the University of Central Florida in Orlando have revived a dormant gene found in humans and coaxed it to produce retrocyclin, a protein that resists HIV.
Lead scientist Alexander Cole used aminoglycosides, drugs commonly used to fight bacterial infections, to trigger the production of the sleeping protein expressed by the retrocyclin gene.
"It could make a huge difference in the fight against HIV," Cole said. "Much more work would be needed to demonstrate the safety and effectiveness of this approach. We would certainly have to have human trials, but these findings represent a promising step in that direction."
Findings from his three-year investigation are published in this month's PLOS Biology, a well-respected scientific journal.
HIV is the virus that causes AIDS. The disease, most often transmitted sexually, affects 4.3 million people worldwide, according to the World Health Organization. About 14,560 people die annually from HIV-related complications each year in the United States alone, according to the Centers for Disease Control.
Dozens of scientists around the world are looking for ways to prevent the transmission of the disease. Cole's journey into this area of research began while he was a postdoctoral fellow in the Department of Medicine at the University of California at Los Angeles. While there, he and his colleagues discovered that similar retrocyclin proteins found in early primates appeared to prevent HIV infections in cell cultures. The same gene exists in humans, but because of a mutation, it no longer produces the protein.
Now, in collaboration with researchers at UCLA, the Centers for Disease Control and his team at UCF, Cole has found that restoring the production of retrocyclins prevents HIV entry. He found a way to get the gene to produce the retrocyclins and then showed that the retrocyclins appear to prevent the transmission of HIV. He applied aminoglycoside antibiotics to vaginal tissues and cervical cells in his lab and found the antibiotic appears to stimulate those cells and tissues to produce retrocyclins on their own.
He said there is a good possibility the aminoglycoside antibiotics will be used in a cream or gel format that could someday be a simple way to prevent the transmission of HIV from men to women.
Cole arrived at UCF in 2003 and continues his work here with more than $4 million in grants from the National Institutes of Health.
Cole has degrees from the College of William and Mary and The University of Medicine and Dentistry of New Jersey. He completed a postdoctoral fellowship at UCLA, and he was an assistant professor in the Department of Medicine at UCLA before teaching at UCF.
He has published more than 50 peer-reviewed articles and has been a grant reviewer for several agencies, including the NIH, the Wellcome Trust and the National Science Foundation.
UCF Stands For Opportunity --The University of Central Florida is a metropolitan research university that ranks as the 5th largest in the nation with more than 50,000 students. UCF's first classes were offered in 1968. The university offers impressive academic and research environments that power the region's economic development. UCF's culture of opportunity is driven by our diversity, Orlando environment, history of entrepreneurship and our youth, relevance and energy. For more information visit http://news.ucf.edu
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.